Cargando…

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug

Detalles Bibliográficos
Autores principales:	Javed, Adil, Reder, Anthony T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733148/ https://www.ncbi.nlm.nih.gov/pubmed/26848488 http://dx.doi.org/10.1212/NXI.0000000000000199

Ejemplares similares

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation
por: Iannetta, Marco, et al.
Publicado: (2016)

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
por: Dwyer, Christopher M., et al.
Publicado: (2021)

Progress Toward Reversed Uterine Diastolic Flow in the Third Trimester - An Inauspicious Sign
por: DINU, MARINA, et al.
Publicado: (2023)

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment
por: Koskimäki, Fredrika, et al.
Publicado: (2018)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Anti-JCV antibody index does not change during ocrelizumab-treatment
por: Rempe, Torge, et al.
Publicado: (2020)

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay
por: Campagnolo, Denise, et al.
Publicado: (2016)

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy
por: Salmen, A., et al.
Publicado: (2016)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study
por: Lambrianides, Sakis, et al.
Publicado: (2019)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
por: Diotti, Roberta Antonia, et al.
Publicado: (2013)

JCV seroconversion rate during the SARS COVID-19 pandemic
por: Vigiser, I., et al.
Publicado: (2022)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017)

Bag3-Induced Autophagy Is Associated with Degradation of JCV Oncoprotein, T-Ag
por: Sariyer, Ilker Kudret, et al.
Publicado: (2012)

No detection of EBV, BKV and JCV in breast cancer tissue samples in Iran
por: Dowran, Razieh, et al.
Publicado: (2019)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Natalizumab in Crohn's disease: past and future areas of applicability
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Fatty Acid-Binding Protein 4—An “Inauspicious” Adipokine—In Serum and Urine of Post-Partum Women with Excessive Gestational Weight Gain and Gestational Diabetes Mellitus
por: Kimber-Trojnar, Żaneta, et al.
Publicado: (2018)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Primary bilateral adrenal B-cell lymphoma associated with EBV and JCV infection
por: Barzon, Luisa, et al.
Publicado: (2009)

JC Virus Encephalopathy Is Associated with a Novel Agnoprotein-Deletion JCV Variant
por: Dang, Xin, et al.
Publicado: (2012)

Encephalitis with coinfection by Jamestown canyon virus (JCV) and varicella zoster virus (VZV)
por: VanderVeen, Nathan, et al.
Publicado: (2020)

Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
por: Foley, John F., et al.
Publicado: (2020)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pibok596ei2t0tamn31d2jhmum